CN113845588A - Preparation method and application of yolk antibody for resisting porcine rotavirus - Google Patents
Preparation method and application of yolk antibody for resisting porcine rotavirus Download PDFInfo
- Publication number
- CN113845588A CN113845588A CN202110577755.8A CN202110577755A CN113845588A CN 113845588 A CN113845588 A CN 113845588A CN 202110577755 A CN202110577755 A CN 202110577755A CN 113845588 A CN113845588 A CN 113845588A
- Authority
- CN
- China
- Prior art keywords
- rva
- immunization
- yolk antibody
- adjuvant
- igy
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000002969 egg yolk Anatomy 0.000 title claims abstract description 36
- 241000702665 Porcine rotavirus Species 0.000 title claims abstract description 16
- 238000002360 preparation method Methods 0.000 title claims abstract description 14
- 230000003053 immunization Effects 0.000 claims abstract description 23
- 238000002649 immunization Methods 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 17
- 229940031551 inactivated vaccine Drugs 0.000 claims abstract description 12
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 235000013601 eggs Nutrition 0.000 claims abstract description 9
- 230000003472 neutralizing effect Effects 0.000 claims abstract description 9
- 230000036039 immunity Effects 0.000 claims abstract description 5
- 206010067470 Rotavirus infection Diseases 0.000 claims abstract description 3
- 241000700605 Viruses Species 0.000 claims description 22
- 239000002671 adjuvant Substances 0.000 claims description 21
- 239000000427 antigen Substances 0.000 claims description 12
- 102000036639 antigens Human genes 0.000 claims description 12
- 108091007433 antigens Proteins 0.000 claims description 12
- 230000002779 inactivation Effects 0.000 claims description 9
- 102000002322 Egg Proteins Human genes 0.000 claims description 8
- 108010000912 Egg Proteins Proteins 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- VEZXCJBBBCKRPI-UHFFFAOYSA-N beta-propiolactone Chemical compound O=C1CCO1 VEZXCJBBBCKRPI-UHFFFAOYSA-N 0.000 claims description 7
- 235000013345 egg yolk Nutrition 0.000 claims description 7
- 229960000380 propiolactone Drugs 0.000 claims description 7
- 230000000937 inactivator Effects 0.000 claims description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 4
- 238000012258 culturing Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 3
- 239000003674 animal food additive Substances 0.000 claims description 2
- -1 divinyl imine Chemical class 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- KAKZBPTYRLMSJV-UHFFFAOYSA-N vinyl-ethylene Natural products C=CC=C KAKZBPTYRLMSJV-UHFFFAOYSA-N 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 10
- 230000003203 everyday effect Effects 0.000 abstract description 2
- 108010001160 IgY Proteins 0.000 description 47
- 238000011282 treatment Methods 0.000 description 26
- 206010012735 Diarrhoea Diseases 0.000 description 19
- 241000282898 Sus scrofa Species 0.000 description 19
- 239000000243 solution Substances 0.000 description 17
- 208000015181 infectious disease Diseases 0.000 description 14
- 102100033633 Killer cell immunoglobulin-like receptor 2DL4 Human genes 0.000 description 12
- 210000004027 cell Anatomy 0.000 description 9
- 230000002265 prevention Effects 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 6
- 238000006386 neutralization reaction Methods 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 241000287828 Gallus gallus Species 0.000 description 4
- 235000013330 chicken meat Nutrition 0.000 description 4
- 210000003022 colostrum Anatomy 0.000 description 4
- 235000021277 colostrum Nutrition 0.000 description 4
- 238000002156 mixing Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 241000282414 Homo sapiens Species 0.000 description 3
- 241000702670 Rotavirus Species 0.000 description 3
- 241001137860 Rotavirus A Species 0.000 description 3
- 241000282887 Suidae Species 0.000 description 3
- 229960003022 amoxicillin Drugs 0.000 description 3
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 description 3
- 239000003242 anti bacterial agent Substances 0.000 description 3
- 230000003115 biocidal effect Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 241000702247 Reoviridae Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 229940031567 attenuated vaccine Drugs 0.000 description 2
- 244000052616 bacterial pathogen Species 0.000 description 2
- 229960002233 benzalkonium bromide Drugs 0.000 description 2
- KHSLHYAUZSPBIU-UHFFFAOYSA-M benzododecinium bromide Chemical compound [Br-].CCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 KHSLHYAUZSPBIU-UHFFFAOYSA-M 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 210000003608 fece Anatomy 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007689 inspection Methods 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 238000011321 prophylaxis Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
- QCVGEOXPDFCNHA-UHFFFAOYSA-N 5,5-dimethyl-2,4-dioxo-1,3-oxazolidine-3-carboxamide Chemical compound CC1(C)OC(=O)N(C(N)=O)C1=O QCVGEOXPDFCNHA-UHFFFAOYSA-N 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 241000191398 Kalanchoe blossfeldiana Species 0.000 description 1
- 239000006142 Luria-Bertani Agar Substances 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- MQUQNUAYKLCRME-INIZCTEOSA-N N-tosyl-L-phenylalanyl chloromethyl ketone Chemical compound C1=CC(C)=CC=C1S(=O)(=O)N[C@H](C(=O)CCl)CC1=CC=CC=C1 MQUQNUAYKLCRME-INIZCTEOSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 108010019160 Pancreatin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 1
- 241000219000 Populus Species 0.000 description 1
- 241000702263 Reovirus sp. Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000007605 air drying Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 238000007664 blowing Methods 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 229960003722 doxycycline Drugs 0.000 description 1
- XQTWDDCIUJNLTR-CVHRZJFOSA-N doxycycline monohydrate Chemical compound O.O=C1C2=C(O)C=CC=C2[C@H](C)[C@@H]2C1=C(O)[C@]1(O)C(=O)C(C(N)=O)=C(O)[C@@H](N(C)C)[C@@H]1[C@H]2O XQTWDDCIUJNLTR-CVHRZJFOSA-N 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 241001493065 dsRNA viruses Species 0.000 description 1
- 235000014103 egg white Nutrition 0.000 description 1
- 210000000969 egg white Anatomy 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000010871 livestock manure Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 229940079901 oral rehydration salt formulations Drugs 0.000 description 1
- 229940055695 pancreatin Drugs 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000002976 pectoralis muscle Anatomy 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000026775 severe diarrhea Diseases 0.000 description 1
- 239000002356 single layer Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 239000007762 w/o emulsion Substances 0.000 description 1
- 238000005491 wire drawing Methods 0.000 description 1
- 244000059546 zoonotic virus Species 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K20/00—Accessory food factors for animal feeding-stuffs
- A23K20/10—Organic substances
- A23K20/142—Amino acids; Derivatives thereof
- A23K20/147—Polymeric derivatives, e.g. peptides or proteins
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23K—FODDER
- A23K50/00—Feeding-stuffs specially adapted for particular animals
- A23K50/30—Feeding-stuffs specially adapted for particular animals for swines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/02—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from eggs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
- C12N2720/00011—Details
- C12N2720/12011—Reoviridae
- C12N2720/12311—Rotavirus, e.g. rotavirus A
- C12N2720/12361—Methods of inactivation or attenuation
- C12N2720/12363—Methods of inactivation or attenuation by chemical treatment
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/14—Reoviridae, e.g. rotavirus, bluetongue virus, Colorado tick fever virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
The invention discloses a preparation method of a yolk antibody against porcine rotavirus, which comprises the following steps: injecting and immunizing the RVA inactivated vaccine prepared by the invention, continuously immunizing for 4 times, and after 2-week interval of each time and 2-immunization, when the neutralizing titer of the antibody reaches 1: and (3) judging the immunity to be qualified when the temperature is over 200 ℃, collecting eggs every day, marking, storing at 4 ℃ for later use, and extracting the yolk antibody IgY. The yolk antibody prepared by the method has certain effect on preventing and treating piglet RVA, can obviously shorten the course of disease, and can be used for preparing products for detecting, preventing and/or treating related diseases caused by porcine rotavirus infection.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a preparation method and application of a yolk antibody for resisting porcine rotavirus.
Background
Group A Rotavirus (RVA) belongs to Reoviridae (Reoviridae), and Rotavirus (Rotavirus) is an unencapsulated double-stranded RNA virus, is an important zoonotic virus, is one of important pathogens causing diarrhea of infants and young animals worldwide, and causes great economic loss. While initially RVA was considered host-specific, increasing epidemiological data now indicate that RVA can be transmitted from animal to human species, and from one animal to another.
Porcine group A rotavirus is an important pathogen causing severe diarrhea of piglets, and the infected piglets mainly show symptoms of diarrhea, dehydration, vomiting, anorexia and the like. The high prevalence of RVA in pigs causes significant economic losses to the swine industry, and treatment of RVA infections can only be symptomatic by replenishing liquids and electrolytes, and there is no effective antiviral treatment. The RVA-specific passive maternal antibodies (local effects) obtained by ingesting colostrum (systemically absorbed and re-secreted into the gut) are also key factors for protecting piglets, but due to placental barrier and insufficient amount of maternal milk ingested by piglets, the method of obtaining maternal antibodies by immunizing sows to let the piglets suckle also cannot completely ensure that the piglets are free from infection. The existing market also has the advantage of using attenuated vaccine to prevent and treat porcine rotavirus, but the time of about one month is needed for generating specific antibody after the attenuated vaccine is immunized, and the death rate of the piglet infected with rotavirus is higher in the period.
Therefore, there is a need to develop an antibody that can rapidly act to control the spread of porcine rotavirus, and reduce the mortality of pigs.
Disclosure of Invention
The invention aims to provide a preparation method and application of a yolk antibody for resisting porcine rotavirus, the yolk antibody prepared by the method has certain effect on preventing and treating piglet RVA, can obviously shorten the course of disease, and can be used for preparing products for detecting, preventing and/or treating related diseases caused by porcine rotavirus infection.
In order to achieve the purpose, the invention provides the technical scheme that:
the invention provides a method for preparing yolk antibody, which comprises injecting inactivated vaccine of G9P [23] RVA virus strain into laying hen for immunization, when the neutralizing titer of antibody reaches 1: collecting eggs when the egg yolk antibody content is more than 200 ℃, and extracting the yolk antibody IgY;
the G9P [23] RVA strain has the accession number V202132.
Chickens are of great interest as a source for the production of antibodies because Immunoglobulin Y (IgY) is deposited in large amounts in the egg yolk, which makes chickens a good source for obtaining large amounts of specific polyclonal antibodies. The antibody yield from egg yolk is estimated to be almost 18 times that from rabbits according to the weight of the antibody produced by each animal, the egg yolk antibody is equivalent to human IgG, the antibody affinity is higher, the specific lgY inhibits the growth, movement and adhesion of pathogenic bacteria through the combination with the pathogenic bacteria, and a large number of experiments prove that the IgY plays an important role in reducing or preventing the degree of diarrhea of human, calves, mice, pigs and the like caused by RV infection. However, the titer and therapeutic effect of IgY antibodies are affected by various factors, such as the type and dosage of the antigen, whether or not an adjuvant is used, the route of immunization, the frequency of vaccination, the age of the layer, and the like. Aiming at the above influencing factors, firstly, the invention selects the inactivated G9P [23] RVA virus strain as antigen to immunize the laying hens, prepares and purifies the IgY of the anti-G9P [23] RVA, and the neutralization titer is as high as 1: 306.
further, the preparation method of the inactivated vaccine of the G9P [23] RVA virus strain comprises the following steps: the virus liquid obtained by recovering and culturing the G9P [23] RVA virus strain is mixed with an inactivator, an inactivated antigen is obtained after inactivation, and then the inactivated antigen is mixed with an adjuvant to obtain the antigen.
Further, the inactivator is selected from one or more of beta-propiolactone, formalin and diethylene imine, and in a specific embodiment of the invention, the inactivator is beta-propiolactone;
further, the mass volume fraction of the beta-propiolactone is 0.025%;
the inactivation conditions are as follows: the temperature is 25-39 ℃, and the inactivation time is 4-24 h;
preferably, the temperature is 37 ℃ and the inactivation time is 12 h.
Further, the inactivated antigen: the volume ratio of the adjuvant is 1: 0.5-2, and preferably 1: 1.
Further, the adjuvant is an oil adjuvant, preferably Freund's complete adjuvant and/or Freund's incomplete adjuvant; in a particular embodiment of the invention, the adjuvants are Freund's complete adjuvant and Freund's incomplete adjuvant.
Further, the immunization method comprises the following steps: 0.5-2 ml is injected for each immunization, 4 times of continuous immunization are carried out, 2 weeks are separated for each immunization, and after the second immunization, when the neutralizing titer of the antibody reaches 1: when the immune response is more than 200, the immune response is qualified.
Further, the laying hens are 100-120 days old.
The invention also provides a yolk antibody against porcine rotavirus, which is prepared by the preparation method.
The invention also provides application of the yolk antibody for resisting the porcine rotavirus in preparing products for detecting, preventing and/or treating related diseases caused by infection of the porcine rotavirus.
Further, the product is selected from one of a preparation, a medicament and a feed additive.
Research proves that (Lixiayu, 2008) IgY almost completely loses activity after being treated by pepsin at 37 ℃ for 1h under the condition of low pH, and the RVA-resistant yolk antibody prepared by the invention can effectively reduce the RVA infection of newborn piglets after being orally taken.
The invention has the following beneficial effects:
the yolk antibody prepared by the method has a neutralizing titer of 1: 306, can be used for the treatment of porcine rotavirus, and the test result shows that the anti-G9P < 23 > RVA IgY prepared by the method of the invention can effectively reduce the infection of RVA of newborn piglets and obviously reduce the morbidity and the fatality rate of the piglets by preventing the newborn piglets; the composition is used for treating the sick piglets aged for more than 7 days, can effectively reduce the fatality rate, can obviously shorten the course of disease for 1-1.3 days, and has better effects on the prevention and treatment of RVA of the piglets.
Drawings
FIG. 1 is a graph of the IgY neutralization titers as a function of immunization time;
FIG. 2 is a graph showing the control effect of anti-G9P [23] RVA IgY;
FIG. 3 is a short course of anti-G9P [23] RVA IgY.
Detailed Description
The technical solutions of the present invention will be described clearly and completely with reference to the accompanying drawings, and it should be understood that the described embodiments are some, but not all embodiments of the present invention. All other embodiments, which can be obtained by a person skilled in the art without any inventive step based on the embodiments of the present invention, are within the scope of the present invention.
The experimental methods in the examples of the present invention are all conventional methods unless otherwise specified, and the experimental materials used therein are all purchased from conventional biochemical reagents, and the data referred to in the examples are average values.
Reagent and experimental animal
Reagent
MA-104 passage cell line, preserved by the animal medicine laboratory of the university of national southwest; porcine strain G9P [23]]RVA(RVA/Pig-tc/CHN/SCJY-13/2017/G9P[23]) The microorganism deposit number of (a) is: v202132; the classification nomenclature is: porcine reovirus RVA/Pig-tc/CHN/SCMY-A3/2017/G9P, Latin literature name is Rotavirus Group A rotaviruses Animal Virus, preservation time: 25/4/2021, depository: china center for type culture CollectionHiding the address: wuhan university in China; TCID50 is 105.5100 mu L; freund's Complete Adjuvant (FCA) and Freund's Incomplete Adjuvant (FIA) were purchased from Sigma.
Laboratory animal
120-feather 110 +/-3-day-old kalanchoe brown young laying hens which are purchased from a certain laying hen breeding company in Sichuan, and basic immunity is finished by the breeding company before purchase; RVA-positive diarrhea pig farm newborn piglets and diarrhea piglets.
Example 1 preparation of G9P [23] RVA inactivated vaccine
(1) And (3) culturing and inactivating viruses: the preserved porcine G9P [23] strain is recovered, cultured and collected, beta-propiolactone inactivator with final concentration of 0.025% is added into the virus liquid, and the virus liquid is inactivated in a shaking incubator at constant temperature of 37 ℃ for 12 h.
(2) Virus inactivation effect test: inoculating the inactivated virus antigen to MA-104 cells, culturing for 48-72 h in a constant-temperature incubator at 37 ℃ and 5% CO2, observing CPE, simultaneously setting up a negative control and an inactivated RVA positive control, if the positive control has typical RVA cytopathy, and the cells inoculated with the inactivated virus solution and the cells of the negative control group have no cytopathy, blindly transferring the cell culture inoculated with the inactivated virus solution for 2 generations, if the CPE is not yet found, indicating that the RVA virus solution is completely inactivated, after blindly transferring the RVA virus solution for 3 generations, having no cytopathy, and the cells inoculated with the inactivated RVA virus solution have typical cytopathic effects such as cell shedding, wire drawing, aggregation and the like.
(3) Mixing the RVA antigen which is completely inactivated by inspection with the FCA/FIA adjuvant with the same volume, and ultrasonically oscillating to form milky viscous water-in-oil emulsion, namely the prepared inactivated vaccine.
And (3) carrying out safety inspection on the prepared inactivated vaccine:
and (3) sterility detection: 100 mu L of the inactivated vaccine is taken and coated on an LB agar culture plate, and no bacteria grow after the inactivated vaccine is cultured for 24 hours at 37 ℃.
And (3) safety detection: the inactivated vaccine is warmed up at room temperature, SPF-grade BALB/c female mice of 6-8 weeks old are respectively inoculated in a mode of subcutaneous multipoint injection on the back, the inoculation dose is 1 mL/mouse, the inoculated BALB/c mice are full of spirit, the appetite is normal, the absorption of injection parts is good, and any adverse abnormal phenomena such as redness and swelling do not occur.
Example 2 preparation of yolk antibody
(1) Immunization of chickens and egg collection
After the laying hens are purchased, the laying hens are adapted for 1 week, 1mL of immune G9P [23] RVA inactivated vaccine is injected into leg and/or chest muscles, continuous immunization is carried out for 4 times, each time is separated by 2 weeks, and after 2-immunization, when the neutralizing titer of antibodies reaches 1: and (3) judging the immunity to be qualified when the temperature is over 200 ℃, collecting eggs every day, marking, and storing at 4 ℃ for later use.
(2) Determination of neutralizing potency of yolk antibody
Randomly collecting 5 eggs every 7d after 2 nd immunization, sterilizing in 0.1% benzalkonium bromide water solution at 42 deg.C for 15min, taking out, air drying, and separating egg yolk with egg white and egg yolk separator; putting the yolk into a sterile beaker, blowing and uniformly mixing, adding 1mL of uniformly mixed yolk into 9mL of deionized water, uniformly mixing, and adjusting the pH value of the yolk solution to 5.0-5.2; after the adjustment is finished, the mixture is placed in a refrigerator with the temperature of 4 ℃ for standing for 4h, supernatant fluid is taken and centrifuged at 6000rpm/min at the temperature of 4 ℃ for 25min, and the supernatant fluid is taken and stored for later use.
The supernatant of the yolk solution was diluted 2-fold in a gradient with DMEM (dilution factor: 2)1、22、23、......、 214) Add it to 2 wells of each dilution in 96 well cell plate, 60 μ Ι _ per well; then adding TPCK pancreatin with final concentration of 30 mug/mL and 5% CO at 37 DEG C2Activating in an incubator for 1h, then diluting the activated virus solution with DMEM to a final concentration of 100TCID50/100 muL virus solution, adding 60 muL virus solution into each well, fully mixing, and incubating in a 37 ℃ 5% CO2 incubator for 1 h; after removing the 96-well plate with the MA-104 cells forming a monolayer and washing 3 times with Hanks' solution, the incubated virus and yolk solution mixture was added to the plate (100. mu.L per well), and finally the cell maintenance solution (50. mu.L per well) was added, and the plate was incubated in a 5% CO2 incubator at 37 ℃ to repeat the experiment 3 times, observing to 6d daily, and recording the number of wells with cytopathic effect (CPE). The neutralization titer of the yolk liquid is calculated by a Reed-muech method, as shown in figure 1:
the specific IgY of G9P RVA can be detected in the first week after the second-time immunization, the IgY slowly rises after the third-time immunization, the IgY rapidly rises in the first week after the fourth-time immunization, and the neutralizing titer of the yolk antibody reaches 1: 210, neutralization titers increased to 1: 408.
(3) extraction and purification of IgY antibody
When the yolk antibody titer reaches 1: collecting 1000 immunized eggs and a small amount of non-immunized eggs, washing chicken manure and the like outside the eggs with distilled water respectively at 200 hours, soaking in 0.1% benzalkonium bromide water solution at 42 ℃ for disinfection for 15min, taking out and drying in the air. The neutralization titer of IgY after purification was determined to be 1: 306.
test example clinical application of yolk antibody
During the period from 10 months to 2021 months in 2020, piglets in 3-scale pig farms in northern Sichuan of Yangyang, Yanshan jiajiang and Meishan of Yangyang have diarrhea of piglets of different ages in different days, which causes certain loss, especially suckling piglets within 1 week of delivery room. Mianyang northern Sichuan SJ pig farm: the incidence rate of diarrhea of piglets within 2 weeks is 75% -100%, the piglets within 2-3 days begin to have diarrhea, and the excrement is yellow with foul smell; le shan jia jiang LS pig farm: in 10 months, the number of diarrhea piglets in a pig farm begins to increase, and the incidence becomes frequent from the usual incidence. Diarrhea occurs from 1 day old to weaning, diarrhea feces are yellow to gray, diarrhea piglets are emaciated, dehydrated and even dead, and vomiting occurs occasionally; meishan MH pig farm: the feed is a commercial pig farm, 240 piglets (12 piglets) of 25 days old are introduced at the beginning of 11 months in 2020, diarrhea begins to appear in two piglets at 8 days after arrival, excrement is gray and gradually presents a water sample, doxycycline and amoxicillin are added into the feed at the beginning, and no obvious effect is seen. The use of antibiotics for prevention and treatment is basically ineffective, and the diseases are slightly relieved by feeding oral rehydration salt and glucose solution, but the effect is slight. Fresh diarrhea stools were collected and tested to confirm RVA infection.
1. anti-G9P [23] RVA IgY for RVA prophylaxis
Mianyang north chuan SJ pig farm 15 litters (172): the anti-RVA IgY is orally taken 2 ml/head piglet before colostrum is sucked in 9 litters (104 heads) of the IgY treatment group, and 6 litters (68 heads) of the control group according to the original antibiotic prevention scheme of a pig farm;
le shan jiajiang LS pig farm 8 litters (78 heads): IgY treatment group 5 litters (48), anti-RVA IgY 2 ml/litter before colostrum intake, control group 3 litters (30), according to the original antibiotic prevention schedule in pig farm. Grouping and processing are shown in Table 1, and results are shown in Table 2.
TABLE 1 IgY RVA prevention test
TABLE 2 anti-RVA IgY for the prophylaxis of RVA in newborn piglets
Note: in the same farm, the right shoulder in the same row differed significantly (p < 0.05).
The results in table 2 show that the oral administration of 2 ml/head of anti-RVA IgY before the newborn piglets eat the colostrums can effectively prevent the diarrhea of the piglets, and remarkably reduce the fatality rate which is respectively 37.5 percent and 70.8 percent; the control group was as high as 72.1% and 100%, respectively.
2. anti-G9P [23] RVA IgY for the treatment of RVA
Treatment of diarrhea in suckling piglets
Mianyang north chuan SJ pig farm suckling piglet 17 litter (175): wherein, 9 litters (93 litters) are 3-7 days old, 5 litters (53 litters) are used in an IgY treatment group, and 4 litters (40 litters) are used in a control group; 8 litters (82) with 8-14 days of age, 4 litters (42) in an IgY treatment group and 4 litters (40) in a control group; the treatment method is the same as that in Table 1.
Le shan jia jiang LS pig farm: 8 litters (72) with age less than 7 days, 4 litters (37) in the IgY treatment group and 4 litters (35) in the control group; 8 litters (67) at 8-14 days of age, 5 litters (43) in IgY treated group and 3 litters (24) in control group. In the IgY treatment group, anti-RVA IgY (less than 7 days old, 2 mL/head; more than 7 days old, 3 mL/head) is injected into whole nest of muscles immediately if diarrhea occurs, and in the control group, all piglets are simultaneously orally taken with liquid supplementing salt according to the original antibiotics in a pig farm. The day of treatment initiation was recorded as day 0 (as in table 3) and the trial observed for continued weaning.
TABLE 3 treatment of RVA infection in suckling piglets
Treatment of diarrhea in weaned piglets
8 weaned (25-30 days old) piglets in an LS pig farm in Leshan mountain (95 heads): 73 heads (column 6) of the IgY treatment group are injected intramuscularly with anti-RVA IgY 4 ml/head, and 24 heads (column 2) of the control group are added with amoxicillin and vitamin complex (shown in table 3).
Brow MH pig farm 200 (10 columns): IgY treatment group 140 heads (column 7), neck intramuscular injection of anti-RVA IgY 4 ml/head; in the control group, 60 populus oral liquid (column 3) is orally taken by 4ml per head, and all pig feeds are added with compound multivitamins and amoxicillin (see table 4).
TABLE 4 treatment of RVA infection in weaned piglets
The treatment conditions of the diarrhea of the suckling piglets and the weaning piglets are shown in the table 5-7.
TABLE 5 therapy of anti-RVA IgY for RVA infection in < 7-day-old piglets
Note: in the same farm, the right shoulders in the same row are obviously different; differences were very significant.
TABLE 6 anti-RVA IgY for the treatment of RVA infection in piglets aged > 7 days
Note: in the same farm, the same row of right shoulders differed significantly.
TABLE 7 anti-RVA IgY for the treatment of RVA infection in weaned piglets
Note: in the same farm, the same row of right shoulders differed significantly.
The results in table 5 show that IgY treated sick piglets less than 7 days old slightly better than the control group; the results in tables 6 and 7 show that when the IgY is used for treating piglets aged for more than 7 days and sick piglets after weaning, the mortality rate can be reduced by the IgY treatment, and the course of disease can be obviously shortened by 1-1.7 days.
Three pig farm data were combined and analyzed, and the results showed: 2mL of anti-G9P [23] RVA IgY is orally taken for preventing RVA infection of newborn piglets, so that the fatality rate (p is less than 0.01) can be remarkably reduced, the average fatality rate of an IgY prevention group is 48.0 percent, and the fatality rate of an antibiotic control group is 80.6 percent (see figure 2); intramuscular injection of 2-4 mL of anti-G9P [23] RVA IgY is not effective in reducing the fatality rate of piglets less than 7 days old and weaned piglets, but can significantly (p < 0.05) reduce the fatality rate of sick piglets 7-14 days old (see FIG. 2); the treatment of intramuscular injection of anti-G9P [23] RVA IgY can remarkably shorten the course of 7-14 days old sick piglets and sick piglets after weaning for 1-1.3 days (see figure 3).
In conclusion, the IgY of anti-G9P [23] RVA prepared by the method has the neutralization potency of 1: 306; the anti-G9P [23] RVA IgY is used for preventing newborn piglets, can effectively reduce the infection of the newborn piglets to the RVA, remarkably reduce the morbidity and the fatality rate of the piglets, shorten the course of disease by 1-1.3 days, and has better effect on the prevention and treatment of the RVA of the piglets.
The above description is only an embodiment of the present invention, and not intended to limit the scope of the present invention, and all changes in equivalent flow or equivalent structure, which are made by using the description of the present invention and are directly or indirectly applied to other related technical fields should be covered by the scope of the present invention.
Claims (10)
1. A method for preparing yolk antibody, which is characterized in that G9P [23] RVA virus strain inactivated vaccine is injected into laying hens for immunization, and when the neutralizing titer of the antibody reaches 1: collecting eggs when the egg yolk antibody content is more than 200 ℃, and extracting the yolk antibody IgY;
the G9P [23] RVA strain has the accession number V202132.
2. The method according to claim 1, wherein the G9P [23] RVA inactivated vaccine is prepared by the method comprising: the virus liquid obtained by recovering and culturing the G9P [23] RVA virus strain is mixed with an inactivator, an inactivated antigen is obtained after inactivation, and then the inactivated antigen is mixed with an adjuvant to obtain the antigen.
3. The preparation method according to claim 2, wherein the inactivator is selected from one or more of beta-propiolactone, formalin, and divinyl imine, preferably beta-propiolactone;
further, the mass volume fraction of the beta-propiolactone is 0.025%;
the inactivation conditions are as follows: the temperature is 25-39 ℃, and the inactivation time is 4-24 h;
preferably, the temperature is 37 ℃ and the inactivation time is 12 h.
4. The method of claim 2, wherein the inactivated antigen: the volume ratio of the adjuvant is 1: 0.5-2, and preferably 1: 1.
5. The process according to claim 2 or 4, wherein the adjuvant is an oil adjuvant, preferably Freund's complete adjuvant and/or Freund's incomplete adjuvant; more preferably Freund's complete adjuvant and Freund's incomplete adjuvant.
6. The method of claim 1, wherein the immunization method comprises: 0.5-2 ml is injected for each immunization, 4 times of continuous immunization are carried out, 2 weeks are separated for each immunization, and after the second immunization, when the neutralizing titer of the antibody reaches 1: when the immunity is above 200, the immunity is qualified.
7. The preparation method according to claim 1, wherein the laying hens are 100-120 days old.
8. A yolk antibody against porcine rotavirus, which is prepared by the preparation method of any one of claims 1 to 7.
9. Use of the yolk antibody against porcine rotavirus of claim 8 in the preparation of products for detecting, preventing and/or treating diseases related to porcine rotavirus infection.
10. Use according to claim 9, wherein the product is selected from one of a formulation, a medicament, a feed additive.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110577755.8A CN113845588B (en) | 2021-05-26 | 2021-05-26 | Preparation method and application of yolk antibody for resisting porcine rotavirus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110577755.8A CN113845588B (en) | 2021-05-26 | 2021-05-26 | Preparation method and application of yolk antibody for resisting porcine rotavirus |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113845588A true CN113845588A (en) | 2021-12-28 |
| CN113845588B CN113845588B (en) | 2023-06-09 |
Family
ID=78973042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110577755.8A Active CN113845588B (en) | 2021-05-26 | 2021-05-26 | Preparation method and application of yolk antibody for resisting porcine rotavirus |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113845588B (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114751978A (en) * | 2022-04-07 | 2022-07-15 | 武汉科前生物股份有限公司 | Porcine rotavirus specific positive serum and preparation method thereof |
Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1980002505A1 (en) * | 1979-05-22 | 1980-11-27 | Gist Brocades Nv | Combined in activated vaccine,ready for administration and process for the preparation of such vaccine,active against egg production drop caused by adeno like viruses and against diseases caused by reo viruses |
| JPH01265034A (en) * | 1988-04-13 | 1989-10-23 | Taiyo Kagaku Co Ltd | Preventive for viral diarrhea |
| JPH0253737A (en) * | 1988-08-12 | 1990-02-22 | Takehiko Yamamoto | Production of polyfunctional specific antibody |
| WO2000052055A1 (en) * | 1999-02-26 | 2000-09-08 | Hartmut Kobilke | SPECIFIC EGG YOLK ANTIBODIES IgY, THE OBTAINMENT AND USE THEREOF |
| CN1484972A (en) * | 2003-08-12 | 2004-03-31 | 石家庄市科星动物保健品有限公司 | Anti-diarrhea yelk antibody feed additive for swine and injection formulation, and preparation method |
| CN102908619A (en) * | 2011-08-04 | 2013-02-06 | 广州格拉姆生物科技有限公司 | Preparation method of egg yolk antibody injection for treating porcine respiratory syndrome |
| CN103694348A (en) * | 2013-12-10 | 2014-04-02 | 刘聚祥 | Preparation and application method for treating swine viral diarrhea biological agent |
| CN104001171A (en) * | 2014-05-26 | 2014-08-27 | 黄光东 | Preparation method of compound IgY for preventing various diarrheas of piglets |
| CN104788561A (en) * | 2014-01-17 | 2015-07-22 | 北京大北农科技集团股份有限公司动物医学研究中心 | Anti-swine transmissible gastroenteritis virus and porcine epidemic diarrhea virus egg-yolk antibody and preparation method thereof |
| CN106729706A (en) * | 2015-11-19 | 2017-05-31 | 鼎正生物药业(天津)有限公司 | A kind of immune response regulation medicine based on IgG antibody |
| CN106806892A (en) * | 2015-12-02 | 2017-06-09 | 天津振邦水产养殖有限公司 | A kind of gut flora regulating drug based on Yolk antibody |
| CN107177001A (en) * | 2016-03-09 | 2017-09-19 | 北京大伟嘉生物技术股份有限公司 | It is a kind of to prevent and treat Yolk antibody of Porcine Epidemic Diarrhea and preparation method thereof |
| CN107880120A (en) * | 2017-11-06 | 2018-04-06 | 陕西诺威利华生物科技有限公司 | A kind of transmissible gastro-enteritis virus Yolk antibody and preparation method thereof |
| CN108220248A (en) * | 2016-12-22 | 2018-06-29 | 普莱柯生物工程股份有限公司 | Porcine rotavirus strain, vaccine composition and its preparation method and application |
| CN113186170A (en) * | 2021-05-26 | 2021-07-30 | 西南民族大学 | Porcine rotavirus strain and inactivated vaccine prepared from same and application of porcine rotavirus strain |
| WO2021194038A1 (en) * | 2020-03-24 | 2021-09-30 | 안병철 | Method for producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof |
-
2021
- 2021-05-26 CN CN202110577755.8A patent/CN113845588B/en active Active
Patent Citations (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1980002505A1 (en) * | 1979-05-22 | 1980-11-27 | Gist Brocades Nv | Combined in activated vaccine,ready for administration and process for the preparation of such vaccine,active against egg production drop caused by adeno like viruses and against diseases caused by reo viruses |
| JPH01265034A (en) * | 1988-04-13 | 1989-10-23 | Taiyo Kagaku Co Ltd | Preventive for viral diarrhea |
| JPH0253737A (en) * | 1988-08-12 | 1990-02-22 | Takehiko Yamamoto | Production of polyfunctional specific antibody |
| WO2000052055A1 (en) * | 1999-02-26 | 2000-09-08 | Hartmut Kobilke | SPECIFIC EGG YOLK ANTIBODIES IgY, THE OBTAINMENT AND USE THEREOF |
| CN1484972A (en) * | 2003-08-12 | 2004-03-31 | 石家庄市科星动物保健品有限公司 | Anti-diarrhea yelk antibody feed additive for swine and injection formulation, and preparation method |
| CN102908619A (en) * | 2011-08-04 | 2013-02-06 | 广州格拉姆生物科技有限公司 | Preparation method of egg yolk antibody injection for treating porcine respiratory syndrome |
| CN103694348A (en) * | 2013-12-10 | 2014-04-02 | 刘聚祥 | Preparation and application method for treating swine viral diarrhea biological agent |
| CN104788561A (en) * | 2014-01-17 | 2015-07-22 | 北京大北农科技集团股份有限公司动物医学研究中心 | Anti-swine transmissible gastroenteritis virus and porcine epidemic diarrhea virus egg-yolk antibody and preparation method thereof |
| CN104001171A (en) * | 2014-05-26 | 2014-08-27 | 黄光东 | Preparation method of compound IgY for preventing various diarrheas of piglets |
| CN106729706A (en) * | 2015-11-19 | 2017-05-31 | 鼎正生物药业(天津)有限公司 | A kind of immune response regulation medicine based on IgG antibody |
| CN106806892A (en) * | 2015-12-02 | 2017-06-09 | 天津振邦水产养殖有限公司 | A kind of gut flora regulating drug based on Yolk antibody |
| CN107177001A (en) * | 2016-03-09 | 2017-09-19 | 北京大伟嘉生物技术股份有限公司 | It is a kind of to prevent and treat Yolk antibody of Porcine Epidemic Diarrhea and preparation method thereof |
| CN108220248A (en) * | 2016-12-22 | 2018-06-29 | 普莱柯生物工程股份有限公司 | Porcine rotavirus strain, vaccine composition and its preparation method and application |
| CN107880120A (en) * | 2017-11-06 | 2018-04-06 | 陕西诺威利华生物科技有限公司 | A kind of transmissible gastro-enteritis virus Yolk antibody and preparation method thereof |
| WO2021194038A1 (en) * | 2020-03-24 | 2021-09-30 | 안병철 | Method for producing serum composition for preventing or treating mucosa-related infectious disease in young mammals, serum composition produced thereby, and use thereof |
| CN113186170A (en) * | 2021-05-26 | 2021-07-30 | 西南民族大学 | Porcine rotavirus strain and inactivated vaccine prepared from same and application of porcine rotavirus strain |
Non-Patent Citations (3)
| Title |
|---|
| C. VEGA 等: "Egg yolk IgY antibodies: A therapeutic intervention against group A rotavirus in calves", 《RESEARCH IN VETERINARY SCIENCE》 * |
| 李玉等: "猪A群轮状病毒RAV/Pig-tc/CHN/SWU-1C/2018/G9P[13]株的分离与鉴定", 《中国预防兽医学报》 * |
| 王元荪: "抗猪腹泻卵黄抗体饲料添加剂和注射剂及其制备方法", 《家禽科学》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114751978A (en) * | 2022-04-07 | 2022-07-15 | 武汉科前生物股份有限公司 | Porcine rotavirus specific positive serum and preparation method thereof |
| CN114751978B (en) * | 2022-04-07 | 2023-10-27 | 武汉科前生物股份有限公司 | Pig rotavirus specific positive serum and preparation method thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113845588B (en) | 2023-06-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN110251671B (en) | Preparation method of goose astrovirus egg yolk antigen-antibody complex | |
| CN104001171A (en) | Preparation method of compound IgY for preventing various diarrheas of piglets | |
| CN112996808A (en) | Compositions and methods for treating acute diarrhea and intestinal infections in animals | |
| CN113845588B (en) | Preparation method and application of yolk antibody for resisting porcine rotavirus | |
| CN1245888C (en) | Anti-diarrhea yelk antibody feed additive for swine and injection formulation, and preparation method | |
| JP3856345B2 (en) | Intestinal protozoan vaccines | |
| RU2428202C1 (en) | Associated vaccine against anaerobic enterotoxemia and colibacillosis diarrhea in calves | |
| US20110129479A1 (en) | Immunogen selection directed in immunoglobulin packages in plasma and colostrum and method of making and using same | |
| EP0930316B1 (en) | Oral product for the prevention and treatment of infectious gastroenteritides in calves | |
| CN109223716B (en) | Quadruple yolk antibody soluble powder for resisting porcine epidemic diarrhea, swine fever, pseudorabies and transmissible gastroenteritis and preparation method thereof | |
| CN108373501A (en) | A kind of composite yolk antibody of resisting fowl bacterial epidemic disease | |
| CN101259271A (en) | Anti-diarrhea yolk antibody feed additive and injection for goat and preparation thereof | |
| US20210252148A1 (en) | Composition and Methods for Preventing and Treating African Swine Fever in Wild and Domestic Swine | |
| CN110862938B (en) | Porcine pathogenic escherichia coli strain and inactivated vaccine thereof | |
| KR100267746B1 (en) | Oral immunological preparation containing egg-yolk antibodies, for prevention and treatment of porcine diarrhea caused by enterotoxigenic escherichia coli | |
| CN1384119A (en) | Composite yolk antibody for resisting fowl's viral blight and its prepn and application | |
| CN112625126A (en) | anti-Hafnia alvei yolk antibody and preparation method and application thereof | |
| WO1996010420A1 (en) | Composition and treatment for hyperimmunization with non heat-killed bacteria | |
| CN111087467A (en) | Preparation method of duck virus hepatitis and duck tongue disease bigeminal polyvalent egg yolk antibody | |
| Van Hamme | Managing intestinal health through a preventative approach | |
| Javadov et al. | Efficacy of live vaccines and specific prevention in chicken infectious bronchitis. | |
| US3704203A (en) | Transmissible gastroenteritis vaccines and methods of producing the same | |
| KR100381553B1 (en) | Manufacturing method of special feed additives using the canine disease antigens | |
| CN102977209A (en) | Preparation method and application of multivalent yolk immunoglobulin for preventing and treating bouine mastitis | |
| CN112079916B (en) | Canine parvovirus egg yolk antibody and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |